Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030193 (
pain
)
261,466
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BACKGROUND The purpose of our study was to determine the functional role of microRNA (miR)-16 in chronic inflammatory
pain
and to disclose its underlying molecular mechanism. MATERIAL AND METHODS Inflammatory pain was induced by injection of complete Freund's adjuvant (CFA) to Wistar rats. The pWPXL-miR-16, PcDNA3.1- Ras-related protein (
RAB23
), and/or SB203580 were delivered intrathecally to the rats. Behavioral tests were detected at 0 h, 4 h, 1 d, 4 d, 7 d, and 14 d after CFA injection. After behavioral tests, L4-L6 dorsal spinal cord were obtained and the levels of miR-16,
RAB23
, and phosphorylation of p38 (p-p38) were evaluated by quantitative real-time PCR (qRT-PCR). In addition, luciferase reporter assay was performed to explore whether
RAB23
was a target of miR-16, and qRT-PCR and Western blotting were used to confirm the regulation between
RAB23
and miR-16. RESULTS The level of miR-16 was significantly decreased in the CFA-induced inflammatory
pain
. Intrathecal injection of miR-16 alleviates
pain
response and raised
pain
threshold. The level of
RAB23
was significantly increased in the
pain
model, and intrathecal injection of
RAB23
aggravated
pain
response. Luciferase reporter assay confirmed that
RAB23
was a direct target of miR-16, and
RAB23
was negatively regulated by miR-16. In addition, we found that simultaneous administration of SB203580 and miR-16 further alleviates
pain
response compared to only administration of miR-16. CONCLUSIONS Our findings suggest that miR-16 relieves chronic inflammatory
pain
by targeting
RAB23
and inhibiting p38 MAPK activation.
...
PMID:MicroRNA-16 Alleviates Inflammatory Pain by Targeting Ras-Related Protein 23 (RAB23) and Inhibiting p38 MAPK Activation. 2777 Jan 29